Research group leader: Martin Ingelsson
Visiting address: Dag Hammarskjölds väg 20, Uppsala Science Park
The aim of our research is to understand, prevent, diagnos and cure diseases in the elderly population, like dementia, diabetes and cardiovascular diease.
In clinical trials we develop new drugs against these diseases. We are conducting epidemiological and genetic studies to understand the interplay between genes and environment in complex disorders. In clinical research we aim to develop better diagnostic instruments for Alzheimer’s disease. Our molecular research is aiming at disease mechanisms of Alzheimer’s disease and related disorders. The starting point for these studies is genetic discoveries to understand molecular mechanisms involved in dementias. Model systems have been developed in transgenic animals and in cell cultures to test new treatment principles.
Enhanced neprilysin-mediated degradation of hippocampal A beta 42 with a somatostatin peptide that enters the brain
Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure
Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability
Preclinical PET imaging and therapy of Alzheimer's disease.
Jinar Rostami (2020)
The role of glial cells in alpha-synuclein pathology: Focus on degradation, cell-to-cell propagation and inflammation.
Kristin Franzon (2019)
Independent Ageing in Very Old Swedish Men.
Leire Almandoz Gil (2018)
Characterization of Physiological and Pathological Alpha-Synuclein: Implications for Parkinson’s Disease and Related Disorders.